Recombinant VEGFR2 (Ramucirumab Biosimilar) anticorps
Aperçu rapide pour Recombinant VEGFR2 (Ramucirumab Biosimilar) anticorps (ABIN7795122)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
Classe de qualité
-
-
Expression System
- Mammalian cells
-
Fonction
- Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody
-
Attributs du produit
- What is ramucirumab biosimilar research grade? Research grade Ramucirumab biosimilar uses the same protein sequences as the therapeutic antibody ramucirumab. Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis. Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of differentiation 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothelial growth factor receptor 2 (VEGFR-2), which is a VEGF receptor. The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC.
-
Purification
- Protein A or G affinity column
-
Pureté
- >95 % by reducing SDS-PAGE
-
niveau d'endotoxine
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogène
- Human VEGFR2
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- VEGFR2 (Ramucirumab Biosimilar)
-
Autre désignation
- Ramucirumab Biosimilar
-
Classe de substances
- Biosimilar
Antigène
-